{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:29:11Z","timestamp":1795080551213,"version":"4.10.2"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Erlangen","id":[{"id":"https:\/\/ror.org\/0030f2a11","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The autophagy-lysosomal pathway is crucial for maintaining homeostasis and survival of neurons, hence defects in this system have been associated with neurodegeneration, including Parkinson's disease (PD). The cysteine proteases cathepsin B (CTSB) and cathepsin L (CTSL) are involved in the clearance of various neurodegenerative disease-related proteins such as amyloid-\n                    <jats:inline-formula>\n                      <jats:tex-math>$$\\:{\\upbeta\\:}$$<\/jats:tex-math>\n                    <\/jats:inline-formula>\n                    , huntingtin and the prion protein. While there are studies implicating CTSB and CTSL as mediators of \u03b1-synuclein\/SNCA clearance, their exact roles remain unclear. We previously demonstrated that recombinant procathepsin D can enhance the clearance of pathological-aggregates of SNCA both in vitro and in vivo, as well as restoring autophagy function. These results prompted us to investigate the role of the two cysteine proteases CTSB and CTSL regarding SNCA degradation by dosing recombinant human procathepsin B (rHsCTSB) and procathepsin L (rHsCTSL) alone or in combination. We here demonstrate that both proteases are efficiently endocytosed by neuronal cells and transported to lysosomes, where they undergo maturation into active enzymes. Treatment with either rHsCTSB or rHsCTSL resulted in a reduction of different SNCA species, present in Triton-insoluble protein fractions as well as sensitive for various pathology- and structure-specific antibodies analyzed via Western blot, immunofluorescence and ELISA. These effects were found to be similar in all models used here: dopaminergic neurons derived from induced pluripotent stem cells (iPSC) of PD patients harboring the SNCA A53T mutation, ex vivo organotypic brain slices and primary neuronal cultures of human SNCA overexpressing Thy1 mice. Interestingly, our data so far do not indicate a synergistic effect of both cysteine cathepsins when applied together. As proof-of-concept for future therapeutic studies, intracranial injections of both recombinant enzymes reduced SNCA in brains of a transgenic mouse model (\n                    <jats:italic>Ctsd<\/jats:italic>\n                    knockout) harboring SNCA pathology. Moreover, treatment with recombinant CTSB and CTSL improved lysosomal\/autophagy functions indicated by recovery of \u03b2-glucocerebrosidase (GCase) activity and SQSTM1 (p62) level. Further, SNCA-dependent synaptic defects as well as toxicity was reduced after treatment of neuronal cells. These findings suggest that enhancing lysosomal CTSB or CTSL effectively degrades pathology-associated SNCA, suggesting a potential therapeutic protease-based strategy for PD and other synucleinopathies.\n                  <\/jats:p>","DOI":"10.1186\/s13024-025-00886-1","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T12:58:40Z","timestamp":1756472320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recombinant cathepsins B and L promote \u03b1-synuclein clearance and restore lysosomal function in human and murine models with \u03b1-synuclein pathology"],"prefix":"10.1186","volume":"20","author":[{"given":"Denise","family":"Balta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susy","family":"Prieto Huarcaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Di Spiezio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 R. A.","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Ya\u011f\u0131z","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do\u011fa","family":"Tabakacilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Drobny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"M\u00e4chtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Philipp","family":"Dobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fejtova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"K\u00fcspert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Saftig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0408-6388","authenticated-orcid":false,"given":"Friederike","family":"Zunke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"issue":"9996","key":"886_CR1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386(9996):896\u2013912.","journal-title":"Lancet"},{"issue":"11","key":"886_CR2","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","volume":"95","author":"MG Spillantini","year":"1998","unstructured":"Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of lewy bodies from parkinson\u2019s disease and dementia with lewy bodies. Proc Natl Acad Sci U S A. 1998;95(11):6469\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"48","key":"886_CR3","doi-asserted-by":"crossref","first-page":"19536","DOI":"10.1021\/ja208657z","volume":"133","author":"O Ullman","year":"2011","unstructured":"Ullman O, Fisher CK, Stultz CM. Explaining the structural plasticity of alpha-synuclein. J Am Chem Soc. 2011;133(48):19536\u201346.","journal-title":"J Am Chem Soc"},{"key":"886_CR4","doi-asserted-by":"crossref","first-page":"666585","DOI":"10.3389\/fchem.2021.666585","volume":"9","author":"N Bisi","year":"2021","unstructured":"Bisi N, Feni L, Peqini K, Perez-Pena H, Ongeri S, Pieraccini S, et al. alpha-Synuclein: an All-Inclusive trip around its structure, influencing factors and applied techniques. Front Chem. 2021;9:666585.","journal-title":"Front Chem"},{"issue":"2","key":"886_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/ng0298-106","volume":"18","author":"R Kruger","year":"1998","unstructured":"Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in parkinson\u2019s disease. Nat Genet. 1998;18(2):106\u20138.","journal-title":"Nat Genet"},{"issue":"5321","key":"886_CR6","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with parkinson\u2019s disease. Science. 1997;276(5321):2045\u20137.","journal-title":"Science"},{"issue":"Suppl 1","key":"886_CR7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.parkreldis.2015.09.007","volume":"22","author":"T Konno","year":"2016","unstructured":"Konno T, Ross OA, Puschmann A, Dickson DW, Wszolek ZK. Autosomal dominant parkinson\u2019s disease caused by SNCA duplications. Parkinsonism Relat Disord. 2016;22(Suppl 1):S1\u20136.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5646","key":"886_CR8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","volume":"302","author":"AB Singleton","year":"2003","unstructured":"Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes parkinson\u2019s disease. Science. 2003;302(5646):841.","journal-title":"Science"},{"issue":"27","key":"886_CR9","doi-asserted-by":"crossref","first-page":"25009","DOI":"10.1074\/jbc.M300227200","volume":"278","author":"JL Webb","year":"2003","unstructured":"Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem. 2003;278(27):25009\u201313.","journal-title":"J Biol Chem"},{"issue":"2","key":"886_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s12035-012-8341-2","volume":"47","author":"M Xilouri","year":"2013","unstructured":"Xilouri M, Brekk OR, Stefanis L. alpha-Synuclein and protein degradation systems: a reciprocal relationship. Mol Neurobiol. 2013;47(2):537\u201351.","journal-title":"Mol Neurobiol"},{"issue":"18","key":"886_CR11","doi-asserted-by":"crossref","first-page":"13621","DOI":"10.1074\/jbc.M109.074617","volume":"285","author":"SK Mak","year":"2010","unstructured":"Mak SK, McCormack AL, Manning-Bog AB, Cuervo AM, Di Monte DA. Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem. 2010;285(18):13621\u20139.","journal-title":"J Biol Chem"},{"issue":"35","key":"886_CR12","doi-asserted-by":"crossref","first-page":"23542","DOI":"10.1074\/jbc.M801992200","volume":"283","author":"T Vogiatzi","year":"2008","unstructured":"Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem. 2008;283(35):23542\u201356.","journal-title":"J Biol Chem"},{"issue":"5688","key":"886_CR13","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1126\/science.1101738","volume":"305","author":"AM Cuervo","year":"2004","unstructured":"Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305(5688):1292\u20135.","journal-title":"Science"},{"issue":"36","key":"886_CR14","doi-asserted-by":"crossref","first-page":"9678","DOI":"10.1021\/bi800699v","volume":"47","author":"D Sevlever","year":"2008","unstructured":"Sevlever D, Jiang P, Yen SH. Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry. 2008;47(36):9678\u201387.","journal-title":"Biochemistry"},{"issue":"30","key":"886_CR15","doi-asserted-by":"crossref","first-page":"9322","DOI":"10.1073\/pnas.1500937112","volume":"112","author":"RP McGlinchey","year":"2015","unstructured":"McGlinchey RP, Lee JC. Cysteine cathepsins are essential in lysosomal degradation of alpha-synuclein. Proc Natl Acad Sci U S A. 2015;112(30):9322\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"886_CR16","doi-asserted-by":"crossref","unstructured":"Prieto Huarcaya S, Drobny A, Marques ARA, Di Spiezio A, Dobert JP, Balta D et al. Recombinant pro-CTSD (cathepsin D) enhances SNCA\/alpha-Synuclein degradation in alpha-Synucleinopathy models. Autophagy. 2022;18(5):1127\u20131151.","DOI":"10.1080\/15548627.2022.2045534"},{"issue":"7","key":"886_CR17","doi-asserted-by":"crossref","first-page":"119243","DOI":"10.1016\/j.bbamcr.2022.119243","volume":"1869","author":"A Drobny","year":"2022","unstructured":"Drobny A, Prieto Huarcaya S, Dobert J, Kluge A, Bunk J, Schlothauer T, et al. The role of lysosomal cathepsins in neurodegeneration: mechanistic insights, diagnostic potential and therapeutic approaches. Biochim Biophys Acta Mol Cell Res. 2022;1869(7):119243.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"886_CR18","doi-asserted-by":"crossref","first-page":"375345","DOI":"10.1155\/2010\/375345","volume":"2010","author":"N Katunuma","year":"2010","unstructured":"Katunuma N. Posttranslational processing and modification of cathepsins and cystatins. J Signal Transduct. 2010;2010:375345.","journal-title":"J Signal Transduct"},{"key":"886_CR19","unstructured":"Cavallo-Medved D, Moin K, Sloane B, Cathepsin B. Basis Sequence: Mouse. AFCS Nat Mol Pages. 2011;2011."},{"issue":"6","key":"886_CR20","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1083\/jcb.104.6.1743","volume":"104","author":"P Lemansky","year":"1987","unstructured":"Lemansky P, Hasilik A, von Figura K, Helmy S, Fishman J, Fine RE, et al. Lysosomal enzyme precursors in coated vesicles derived from the Exocytic and endocytic pathways. J Cell Biol. 1987;104(6):1743\u20138.","journal-title":"J Cell Biol"},{"issue":"3","key":"886_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00418-008-0384-0","volume":"129","author":"E van Meel","year":"2008","unstructured":"van Meel E, Klumperman J. Imaging and imagination: Understanding the endo-lysosomal system. Histochem Cell Biol. 2008;129(3):253\u201366.","journal-title":"Histochem Cell Biol"},{"issue":"1","key":"886_CR22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0003-9861(88)90104-X","volume":"261","author":"Y Nishimura","year":"1988","unstructured":"Nishimura Y, Kawabata T, Kato K. Identification of latent procathepsins B and L in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Arch Biochem Biophys. 1988;261(1):64\u201371.","journal-title":"Arch Biochem Biophys"},{"key":"886_CR23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-3-7091-0885-7_4","volume-title":"Proteases: structure and function","author":"AH Erickson","year":"2013","unstructured":"Erickson AH, Isidoro C, Mach L, Mort JS. Cathepsins: getting in shape for lysosomal proteolysis. In: Brix K, St\u00f6cker W, editors. Proteases: structure and function. Vienna: Springer Vienna; 2013. pp. 127\u201373."},{"issue":"10","key":"886_CR24","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/ng.3955","volume":"49","author":"D Chang","year":"2017","unstructured":"Chang D, Nalls MA, Hallgrimsdottir IB, Hunkapiller J, van der Brug M, Cai F, et al. A meta-analysis of genome-wide association studies identifies 17 new parkinson\u2019s disease risk loci. Nat Genet. 2017;49(10):1511\u20136.","journal-title":"Nat Genet"},{"issue":"12","key":"886_CR25","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1093\/brain\/awx285","volume":"140","author":"LA Robak","year":"2017","unstructured":"Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J, et al. Excessive burden of lysosomal storage disorder gene variants in parkinson\u2019s disease. Brain. 2017;140(12):3191\u2013203.","journal-title":"Brain"},{"issue":"12","key":"886_CR26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091\u2013102.","journal-title":"Lancet Neurol"},{"issue":"6743","key":"886_CR27","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1126\/science.adq6650","volume":"388","author":"G Minakaki","year":"2025","unstructured":"Minakaki G, Safren N, Bustos BI, Lubbe SJ, Mencacci NE, Krainc D. Commander complex regulates lysosomal function and is implicated in parkinson\u2019s disease risk. Science. 2025;388(6743):204\u201311.","journal-title":"Science"},{"issue":"9","key":"886_CR28","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/mds.23774","volume":"26","author":"T Shachar","year":"2011","unstructured":"Shachar T, Lo Bianco C, Recchia A, Wiessner C, Raas-Rothschild A, Futerman AH. Lysosomal storage disorders and parkinson\u2019s disease: gaucher disease and beyond. Mov Disord. 2011;26(9):1593\u2013604.","journal-title":"Mov Disord"},{"key":"886_CR29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.parkreldis.2019.11.015","volume":"73","author":"K Senkevich","year":"2020","unstructured":"Senkevich K, Gan-Or Z. Autophagy lysosomal pathway dysfunction in parkinson\u2019s disease; evidence from human genetics. Parkinsonism Relat Disord. 2020;73:60\u201371.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"886_CR30","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41467-019-08912-9","volume":"10","author":"YI Li","year":"2019","unstructured":"Li YI, Wong G, Humphrey J, Raj T. Prioritizing parkinson\u2019s disease genes using population-scale transcriptomic data. Nat Commun. 2019;10(1):994.","journal-title":"Nat Commun"},{"key":"886_CR31","doi-asserted-by":"crossref","first-page":"1394807","DOI":"10.3389\/fnagi.2024.1394807","volume":"16","author":"L Lin","year":"2024","unstructured":"Lin L, Wu Z, Luo H, Huang Y. Cathepsin-mediated regulation of alpha-synuclein in parkinson\u2019s disease: a Mendelian randomization study. Front Aging Neurosci. 2024;16:1394807.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"886_CR32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/brain\/awz350","volume":"143","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat C, Reed X, Krohn L, Heilbron K, Bandres-Ciga S, Tan M, et al. Genetic modifiers of risk and age at onset in GBA associated parkinson\u2019s disease and lewy body dementia. Brain. 2020;143(1):234\u201348.","journal-title":"Brain"},{"key":"886_CR33","doi-asserted-by":"crossref","unstructured":"Milanowski LM, Hou X, Bredenberg JM, Fiesel FC, Cocker LT, Soto-Beasley AI et al. Cathepsin B p.Gly284Val Variant in Parkinson\u2019s Disease Pathogenesis. Int J Mol Sci. 2022;23(13).","DOI":"10.3390\/ijms23137086"},{"issue":"1","key":"886_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40035-023-00363-z","volume":"12","author":"A Drobny","year":"2023","unstructured":"Drobny A, Boros FA, Balta D, Prieto Huarcaya S, Caylioglu D, Qazi N, et al. Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models. Transl Neurodegener. 2023;12(1):31.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"886_CR35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146(1):37\u201352.","journal-title":"Cell"},{"issue":"9","key":"886_CR36","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1073\/pnas.1616332114","volume":"114","author":"S Jinn","year":"2017","unstructured":"Jinn S, Drolet RE, Cramer PE, Wong AH, Toolan DM, Gretzula CA, et al. TMEM175 deficiency impairs lysosomal and mitochondrial function and increases alpha-synuclein aggregation. Proc Natl Acad Sci U S A. 2017;114(9):2389\u201394.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"886_CR37","doi-asserted-by":"crossref","unstructured":"Kim MJ, Jeong H, Krainc D. Lysosomal ceramides regulate cathepsin B-mediated processing of Saposin C and glucocerebrosidase activity. Hum Mol Genet. 2022;31(14):2424\u20132437.","DOI":"10.1093\/hmg\/ddac047"},{"issue":"6","key":"886_CR38","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1007\/s11596-018-1977-z","volume":"38","author":"D Hu","year":"2018","unstructured":"Hu D, Niu JY, Xiong J, Nie SK, Zeng F, Zhang ZH. LRRK2 G2019S mutation inhibits degradation of alpha-Synuclein in an in vitro model of parkinson\u2019s disease. Curr Med Sci. 2018;38(6):1012\u20137.","journal-title":"Curr Med Sci"},{"issue":"25","key":"886_CR39","doi-asserted-by":"crossref","first-page":"9973","DOI":"10.1074\/jbc.RA119.008930","volume":"294","author":"RP McGlinchey","year":"2019","unstructured":"McGlinchey RP, Lacy SM, Huffer KE, Tayebi N, Sidransky E, Lee JC. C-terminal alpha-synuclein truncations are linked to cysteine cathepsin activity in parkinson\u2019s disease. J Biol Chem. 2019;294(25):9973\u201384.","journal-title":"J Biol Chem"},{"issue":"1","key":"886_CR40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13024-024-00779-9","volume":"19","author":"J Jones-Tabah","year":"2024","unstructured":"Jones-Tabah J, He K, Karpilovsky N, Senkevich K, Deyab G, Pietrantonio I, et al. The parkinson\u2019s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons. Mol Neurodegener. 2024;19(1):88.","journal-title":"Mol Neurodegener"},{"issue":"30","key":"886_CR41","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1021\/acs.biochem.7b00360","volume":"56","author":"RP McGlinchey","year":"2017","unstructured":"McGlinchey RP, Dominah GA, Lee JC. Taking a bite out of amyloid: mechanistic insights into alpha-Synuclein degradation by cathepsin L. Biochemistry. 2017;56(30):3881\u20134.","journal-title":"Biochemistry"},{"issue":"2","key":"886_CR42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/yea.3286","volume":"35","author":"MK Streubel","year":"2018","unstructured":"Streubel MK, Bischof J, Weiss R, Duschl J, Liedl W, Wimmer H, et al. Behead and live long or the Tale of cathepsin L. Yeast. 2018;35(2):237\u201349.","journal-title":"Yeast"},{"issue":"2","key":"886_CR43","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s13311-012-0104-2","volume":"9","author":"MF Chesselet","year":"2012","unstructured":"Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR. A progressive mouse model of parkinson\u2019s disease: the Thy1-aSyn (Line 61) mice. Neurotherapeutics. 2012;9(2):297\u2013314.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"886_CR44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13311-022-01338-0","volume":"20","author":"F Richter","year":"2023","unstructured":"Richter F, Stanojlovic M, Kaufer C, Gericke B, Feja M. A mouse model to test novel therapeutics for parkinson\u2019s disease: an update on the Thy1-aSyn (line 61) mice. Neurotherapeutics. 2023;20(1):97\u2013116.","journal-title":"Neurotherapeutics"},{"key":"886_CR45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-6606-2-5","volume":"2","author":"V Cullen","year":"2009","unstructured":"Cullen V, Lindfors M, Ng J, Paetau A, Swinton E, Kolodziej P, et al. Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol Brain. 2009;2:5.","journal-title":"Mol Brain"},{"key":"886_CR46","doi-asserted-by":"crossref","unstructured":"Qiao LY, Hamamichi S, Caldwell KA, Caldwell GA, Yacoubian TA, Wilson S et al. Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain. 2008;1.","DOI":"10.1186\/1756-6606-1-17"},{"issue":"5","key":"886_CR47","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/15548627.2019.1637200","volume":"16","author":"ARA Marques","year":"2020","unstructured":"Marques ARA, Di Spiezio A, Thiessen N, Schmidt L, Grotzinger J, Lullmann-Rauch R, et al. Enzyme replacement therapy with Recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis. Autophagy. 2020;16(5):811\u201325.","journal-title":"Autophagy"},{"key":"886_CR48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mcn.2013.01.004","volume":"54","author":"W Xiang","year":"2013","unstructured":"Xiang W, Schlachetzki JC, Helling S, Bussmann JC, Berlinghof M, Schaffer TE, et al. Oxidative stress-induced posttranslational modifications of alpha-synuclein: specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity. Mol Cell Neurosci. 2013;54:71\u201383.","journal-title":"Mol Cell Neurosci"},{"key":"886_CR49","doi-asserted-by":"crossref","first-page":"581805","DOI":"10.3389\/fcell.2021.581805","volume":"9","author":"J Bunk","year":"2021","unstructured":"Bunk J, Prieto Huarcaya S, Drobny A, Dobert JP, Walther L, Rose-John S, et al. Cathepsin D variants associated with neurodegenerative diseases show dysregulated functionality and modified alpha-Synuclein degradation properties. Front Cell Dev Biol. 2021;9:581805.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"886_CR50","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cell.2011.06.019","volume":"146","author":"F Soldner","year":"2011","unstructured":"Soldner F, Laganiere J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell. 2011;146(2):318\u201331.","journal-title":"Cell"},{"issue":"7378","key":"886_CR51","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10648","volume":"480","author":"S Kriks","year":"2011","unstructured":"Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of parkinson\u2019s disease. Nature. 2011;480(7378):547\u201351.","journal-title":"Nature"},{"issue":"10","key":"886_CR52","doi-asserted-by":"crossref","first-page":"166205","DOI":"10.1016\/j.bbadis.2021.166205","volume":"1867","author":"A Di Spiezio","year":"2021","unstructured":"Di Spiezio A, Marques ARA, Schmidt L, Thiessen N, Gallwitz L, Fogh J, et al. Analysis of cathepsin B and cathepsin L treatment to clear toxic lysosomal protein aggregates in neuronal ceroid lipofuscinosis. Biochim Biophys Acta Mol Basis Dis. 2021;1867(10):166205.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"25","key":"886_CR53","doi-asserted-by":"crossref","first-page":"e2401641","DOI":"10.1002\/advs.202401641","volume":"11","author":"JP Dobert","year":"2024","unstructured":"Dobert JP, Bub S, Machtel R, Januliene D, Steger L, Regensburger M, et al. Activation and purification of ss-Glucocerebrosidase by exploiting its transporter LIMP-2 - Implications for novel treatment strategies in gaucher\u2019s and parkinson\u2019s disease. Adv Sci (Weinh). 2024;11(25):e2401641.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"886_CR54","doi-asserted-by":"crossref","first-page":"100372","DOI":"10.1016\/j.xpro.2021.100372","volume":"2","author":"I Stojkovska","year":"2021","unstructured":"Stojkovska I, Mazzulli JR. Detection of pathological alpha-synuclein aggregates in human iPSC-derived neurons and tissue. STAR Protoc. 2021;2(1):100372.","journal-title":"STAR Protoc"},{"issue":"30","key":"886_CR55","doi-asserted-by":"crossref","first-page":"7813","DOI":"10.1073\/pnas.1713129115","volume":"115","author":"I Prots","year":"2018","unstructured":"Prots I, Grosch J, Brazdis RM, Simmnacher K, Veber V, Havlicek S, et al. alpha-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies. Proc Natl Acad Sci U S A. 2018;115(30):7813\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"886_CR56","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1021\/acs.biomac.0c00629","volume":"21","author":"B Eymsh","year":"2020","unstructured":"Eymsh B, Drobny A, Heyn TR, Xiang W, Lucius R, Schwarz K, et al. Toxic Metamorphosis-How changes from lysosomal to cytosolic pH modify the Alpha-Synuclein aggregation pattern. Biomacromolecules. 2020;21(12):4673\u201384.","journal-title":"Biomacromolecules"},{"issue":"757","key":"886_CR57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.30.757.23","volume":"30","author":"K Pearson","year":"1909","unstructured":"Pearson K. Determination of the coefficient of correlation. Science. 1909;30(757):23\u20135.","journal-title":"Science"},{"issue":"7","key":"886_CR58","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676\u201382.","journal-title":"Nat Methods"},{"issue":"6 Pt 1","key":"886_CR59","doi-asserted-by":"crossref","first-page":"C1069","DOI":"10.1152\/ajpcell.1989.257.6.C1069","volume":"257","author":"AM Samarel","year":"1989","unstructured":"Samarel AM, Ferguson AG, Decker RS, Lesch M. Effects of cysteine protease inhibitors on rabbit cathepsin D maturation. Am J Physiol. 1989;257(6 Pt 1):C1069\u201379.","journal-title":"Am J Physiol"},{"issue":"4","key":"886_CR60","first-page":"879","volume":"152","author":"M Baba","year":"1998","unstructured":"Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, et al. Aggregation of alpha-synuclein in lewy bodies of sporadic parkinson\u2019s disease and dementia with lewy bodies. Am J Pathol. 1998;152(4):879\u201384.","journal-title":"Am J Pathol"},{"issue":"1","key":"886_CR61","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41531-023-00604-y","volume":"9","author":"MF Altay","year":"2023","unstructured":"Altay MF, Kumar ST, Burtscher J, Jagannath S, Strand C, Miki Y, et al. Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in lewy body diseases. NPJ Parkinsons Dis. 2023;9(1):161.","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"886_CR62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13024-023-00680-x","volume":"18","author":"N Ramalingam","year":"2023","unstructured":"Ramalingam N, Dettmer U. alpha-Synuclein serine129 phosphorylation - the physiology of pathology. Mol Neurodegener. 2023;18(1):84.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"886_CR63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41531-023-00444-w","volume":"9","author":"N Ramalingam","year":"2023","unstructured":"Ramalingam N, Jin SX, Moors TE, Fonseca-Ornelas L, Shimanaka K, Lei S, et al. Dynamic physiological alpha-synuclein S129 phosphorylation is driven by neuronal activity. NPJ Parkinsons Dis. 2023;9(1):4.","journal-title":"NPJ Parkinsons Dis"},{"issue":"7","key":"886_CR64","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.tins.2024.05.005","volume":"47","author":"N Ramalingam","year":"2024","unstructured":"Ramalingam N, Haass C, Dettmer U. Physiological roles of alpha-synuclein serine-129 phosphorylation - not an oxymoron. Trends Neurosci. 2024;47(7):480\u201390.","journal-title":"Trends Neurosci"},{"issue":"2","key":"886_CR65","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ana.10279","volume":"52","author":"JE Duda","year":"2002","unstructured":"Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in lewy body diseases. Ann Neurol. 2002;52(2):205\u201310.","journal-title":"Ann Neurol"},{"issue":"15","key":"886_CR66","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1002\/j.1460-2075.1995.tb00029.x","volume":"14","author":"P Saftig","year":"1995","unstructured":"Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H, et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J. 1995;14(15):3599\u2013608.","journal-title":"EMBO J"},{"issue":"1","key":"886_CR67","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1038\/s41467-022-33252-6","volume":"13","author":"D Emin","year":"2022","unstructured":"Emin D, Zhang YP, Lobanova E, Miller A, Li X, Xia Z, et al. Small soluble alpha-synuclein aggregates are the toxic species in parkinson\u2019s disease. Nat Commun. 2022;13(1):5512.","journal-title":"Nat Commun"},{"issue":"5","key":"886_CR68","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jnr.10231","volume":"68","author":"E Rockenstein","year":"2002","unstructured":"Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, et al. Differential neuropathological alterations in Transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res. 2002;68(5):568\u201378.","journal-title":"J Neurosci Res"},{"key":"886_CR69","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1749-6632.2003.tb07475.x","volume":"991","author":"M Hashimoto","year":"2003","unstructured":"Hashimoto M, Rockenstein E, Masliah E. Transgenic models of alpha-synuclein pathology: past, present, and future. Ann N Y Acad Sci. 2003;991:171\u201388.","journal-title":"Ann N Y Acad Sci"},{"key":"886_CR70","doi-asserted-by":"crossref","first-page":"105478","DOI":"10.1016\/j.nbd.2021.105478","volume":"158","author":"ERS Torres","year":"2021","unstructured":"Torres ERS, Stanojlovic M, Zelikowsky M, Bonsberger J, Hean S, Mulligan C, et al. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of parkinson\u2019s disease. Neurobiol Dis. 2021;158:105478.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"886_CR71","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41531-024-00822-y","volume":"10","author":"I Lieknina","year":"2024","unstructured":"Lieknina I, Reimer L, Pantelejevs T, Lends A, Jaudzems K, El-Turabi A, et al. Structural basis of epitope recognition by anti-alpha-synuclein antibodies MJFR14-6-4-2. NPJ Parkinsons Dis. 2024;10(1):206.","journal-title":"NPJ Parkinsons Dis"},{"issue":"8","key":"886_CR72","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1093\/brain\/awy147","volume":"141","author":"AD Klein","year":"2018","unstructured":"Klein AD, Mazzulli JR. Is parkinson\u2019s disease a lysosomal disorder? Brain. 2018;141(8):2255\u201362.","journal-title":"Brain"},{"issue":"9","key":"886_CR73","doi-asserted-by":"crossref","first-page":"140443","DOI":"10.1016\/j.bbapap.2020.140443","volume":"1868","author":"RA Nixon","year":"2020","unstructured":"Nixon RA. The aging lysosome: an essential catalyst for late-onset neurodegenerative diseases. Biochim Biophys Acta Proteins Proteom. 2020;1868(9):140443.","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"issue":"9","key":"886_CR74","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1474-4422(18)30238-2","volume":"17","author":"A Scrivo","year":"2018","unstructured":"Scrivo A, Bourdenx M, Pampliega O, Cuervo AM. Selective autophagy as a potential therapeutic target for neurodegenerative disorders. Lancet Neurol. 2018;17(9):802\u201315.","journal-title":"Lancet Neurol"},{"issue":"1","key":"886_CR75","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00018-024-05274-4","volume":"81","author":"L Gallwitz","year":"2024","unstructured":"Gallwitz L, Bleibaum F, Voss M, Schweizer M, Spengler K, Winter D, et al. Cellular depletion of major cathepsin proteases reveals their concerted activities for lysosomal proteolysis. Cell Mol Life Sci. 2024;81(1):227.","journal-title":"Cell Mol Life Sci"},{"key":"886_CR76","doi-asserted-by":"crossref","unstructured":"Yadati T, Houben T, Bitorina A, Shiri-Sverdlov R. The Ins and outs of cathepsins: physiological function and role in disease management. Cells. 2020;9(7).","DOI":"10.3390\/cells9071679"},{"issue":"11","key":"886_CR77","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1523\/JNEUROSCI.17-11-04006.1997","volume":"17","author":"E Bednarski","year":"1997","unstructured":"Bednarski E, Ribak CE, Lynch G. Suppression of cathepsins B and L causes a proliferation of lysosomes and the formation of meganeurites in hippocampus. J Neurosci. 1997;17(11):4006\u201321.","journal-title":"J Neurosci"},{"issue":"7","key":"886_CR78","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1515\/BC.2006.112","volume":"387","author":"L Sevenich","year":"2006","unstructured":"Sevenich L, Pennacchio LA, Peters C, Reinheckel T. Human cathepsin L rescues the neurodegeneration and lethality in cathepsin B\/L double-deficient mice. Biol Chem. 2006;387(7):885\u201391.","journal-title":"Biol Chem"},{"issue":"12","key":"886_CR79","doi-asserted-by":"crossref","first-page":"7883","DOI":"10.1073\/pnas.112632299","volume":"99","author":"U Felbor","year":"2002","unstructured":"Felbor U, Kessler B, Mothes W, Goebel HH, Ploegh HL, Bronson RT, et al. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc Natl Acad Sci U S A. 2002;99(12):7883\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"886_CR80","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1515\/bc.2011.054","volume":"392","author":"I Schechter","year":"2011","unstructured":"Schechter I, Ziv E, Cathepsins S. B and L with aminopeptidases display beta-secretase activity associated with the pathogenesis of alzheimer\u2019s disease. Biol Chem. 2011;392(6):555\u201369.","journal-title":"Biol Chem"},{"issue":"6","key":"886_CR81","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.neuron.2006.07.027","volume":"51","author":"S Mueller-Steiner","year":"2006","unstructured":"Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for alzheimer\u2019s disease. Neuron. 2006;51(6):703\u201314.","journal-title":"Neuron"},{"issue":"3","key":"886_CR82","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1124\/jpet.108.147082","volume":"328","author":"DM Klein","year":"2009","unstructured":"Klein DM, Felsenstein KM, Brenneman DE. Cathepsins B and L differentially regulate amyloid precursor protein processing. J Pharmacol Exp Ther. 2009;328(3):813\u201321.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"886_CR83","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0950-3536(97)80042-X","volume":"10","author":"PK Mistry","year":"1997","unstructured":"Mistry PK, Abrahamov A. A practical approach to diagnosis and management of gaucher\u2019s disease. Baillieres Clin Haematol. 1997;10(4):817\u201338.","journal-title":"Baillieres Clin Haematol"},{"issue":"7","key":"886_CR84","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1073\/pnas.75.7.3327","volume":"75","author":"S Ohkuma","year":"1978","unstructured":"Ohkuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A. 1978;75(7):3327\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"886_CR85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1083\/jcb.96.1.1","volume":"96","author":"RM Steinman","year":"1983","unstructured":"Steinman RM, Mellman IS, Muller WA, Cohn ZA. Endocytosis and the recycling of plasma membrane. J Cell Biol. 1983;96(1):1\u201327.","journal-title":"J Cell Biol"},{"issue":"11","key":"886_CR86","doi-asserted-by":"crossref","first-page":"e0167428","DOI":"10.1371\/journal.pone.0167428","volume":"11","author":"S Cermak","year":"2016","unstructured":"Cermak S, Kosicek M, Mladenovic-Djordjevic A, Smiljanic K, Kanazir S, Hecimovic S. Loss of cathepsin B and L leads to lysosomal dysfunction, NPC-Like cholesterol sequestration and accumulation of the key alzheimer\u2019s proteins. PLoS ONE. 2016;11(11):e0167428.","journal-title":"PLoS ONE"},{"issue":"47","key":"886_CR87","doi-asserted-by":"crossref","first-page":"39834","DOI":"10.1074\/jbc.M112.371641","volume":"287","author":"C Wang","year":"2012","unstructured":"Wang C, Sun B, Zhou Y, Grubb A, Gan L. Cathepsin B degrades amyloid-beta in mice expressing wild-type human amyloid precursor protein. J Biol Chem. 2012;287(47):39834\u201341.","journal-title":"J Biol Chem"},{"issue":"2","key":"886_CR88","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11481-016-9721-6","volume":"12","author":"CM Embury","year":"2017","unstructured":"Embury CM, Dyavarshetty B, Lu Y, Wiederin JL, Ciborowski P, Gendelman HE, et al. Cathepsin B improves ss-Amyloidosis and learning and memory in models of alzheimer\u2019s disease. J Neuroimmune Pharmacol. 2017;12(2):340\u201352.","journal-title":"J Neuroimmune Pharmacol"},{"key":"886_CR89","doi-asserted-by":"crossref","unstructured":"Hwang J, Estick CM, Ikonne US, Butler D, Pait MC, Elliott LH et al. The Role of Lysosomes in a Broad Disease-Modifying Approach Evaluated across Transgenic Mouse Models of Alzheimer\u2019s Disease and Parkinson\u2019s Disease and Models of Mild Cognitive Impairment. Int J Mol Sci. 2019;20(18).","DOI":"10.3390\/ijms20184432"},{"issue":"1","key":"886_CR90","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0197-4580(03)00034-4","volume":"25","author":"B Boland","year":"2004","unstructured":"Boland B, Campbell V. Abeta-mediated activation of the apoptotic cascade in cultured cortical neurones: a role for cathepsin-L. Neurobiol Aging. 2004;25(1):83\u201391.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"886_CR91","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.neuron.2017.12.012","volume":"97","author":"F Zunke","year":"2018","unstructured":"Zunke F, Moise AC, Belur NR, Gelyana E, Stojkovska I, Dzaferbegovic H, et al. Reversible conformational conversion of alpha-Synuclein into toxic assemblies by glucosylceramide. Neuron. 2018;97(1):92\u2013e10710.","journal-title":"Neuron"},{"issue":"1","key":"886_CR92","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1038\/s41467-023-37454-4","volume":"14","author":"P Baden","year":"2023","unstructured":"Baden P, Perez MJ, Raji H, Bertoli F, Kalb S, Illescas M, et al. Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism. Nat Commun. 2023;14(1):1930.","journal-title":"Nat Commun"},{"issue":"1","key":"886_CR93","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41531-024-00830-y","volume":"10","author":"BG Trist","year":"2024","unstructured":"Trist BG, Wright CJ, Rangel A, Cottle L, Prasad A, Jensen NM, et al. Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain. NPJ Parkinsons Dis. 2024;10(1):217.","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"886_CR94","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41467-020-20185-1","volume":"12","author":"S Kageyama","year":"2021","unstructured":"Kageyama S, Gudmundsson SR, Sou YS, Ichimura Y, Tamura N, Kazuno S, et al. p62\/SQSTM1-droplet serves as a platform for autophagosome formation and anti-oxidative stress response. Nat Commun. 2021;12(1):16.","journal-title":"Nat Commun"},{"key":"886_CR95","doi-asserted-by":"crossref","unstructured":"Kim MJ, Kim S, Reinheckel T, Krainc D. Inhibition of cysteine protease cathepsin L increases the level and activity of lysosomal glucocerebrosidase. JCI Insight. 2024;9(3).","DOI":"10.1172\/jci.insight.169594"},{"key":"886_CR96","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev-physiol-012110-142317","volume":"74","author":"JA Mindell","year":"2012","unstructured":"Mindell JA. Lysosomal acidification mechanisms. Annu Rev Physiol. 2012;74:69\u201386.","journal-title":"Annu Rev Physiol"},{"key":"886_CR97","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-2091-10-23","volume":"10","author":"S Jordans","year":"2009","unstructured":"Jordans S, Jenko-Kokalj S, Kuhl NM, Tedelind S, Sendt W, Bromme D, et al. Monitoring compartment-specific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions. BMC Biochem. 2009;10:23.","journal-title":"BMC Biochem"},{"key":"886_CR98","doi-asserted-by":"crossref","unstructured":"Chugunov AO, Dvoryakova EA, Dyuzheva MA, Simonyan TR, Tereshchenkova VF, Filippova IY et al. Fighting Celiac disease: improvement of pH stability of cathepsin L in vitro by computational design. Int J Mol Sci. 2023;24(15).","DOI":"10.3390\/ijms241512369"},{"issue":"13","key":"886_CR99","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.cell.2022.05.021","volume":"185","author":"M Hu","year":"2022","unstructured":"Hu M, Li P, Wang C, Feng X, Geng Q, Chen W, et al. Parkinson\u2019s disease-risk protein TMEM175 is a proton-activated proton channel in lysosomes. Cell. 2022;185(13):2292\u2013308. e20.","journal-title":"Cell"},{"key":"886_CR100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neuroscience.2015.07.086","volume":"305","author":"C Humpel","year":"2015","unstructured":"Humpel C. Organotypic brain slice cultures: A review. Neuroscience. 2015;305:86\u201398.","journal-title":"Neuroscience"},{"issue":"2","key":"886_CR101","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2174\/1567205016666181212153138","volume":"16","author":"C Humpel","year":"2019","unstructured":"Humpel C. Organotypic brain slices of ADULT Transgenic mice: A tool to study alzheimer\u2019s disease. Curr Alzheimer Res. 2019;16(2):172\u201381.","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"886_CR102","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13024-019-0346-0","volume":"14","author":"CL Croft","year":"2019","unstructured":"Croft CL, Futch HS, Moore BD, Golde TE. Organotypic brain slice cultures to model neurodegenerative proteinopathies. Mol Neurodegener. 2019;14(1):45.","journal-title":"Mol Neurodegener"},{"issue":"3","key":"886_CR103","doi-asserted-by":"publisher","first-page":"e2671","DOI":"10.1038\/cddis.2017.97","volume":"8","author":"CL Croft","year":"2017","unstructured":"Croft CL, Wade MA, Kurbatskaya K, Mastrandreas P, Hughes MM, Phillips EC, et al. Membrane association and release of wild-type and pathological Tau from organotypic brain slice cultures. Cell Death Dis. 2017;8(3):e2671.","journal-title":"Cell Death Dis"},{"issue":"23","key":"886_CR104","doi-asserted-by":"crossref","first-page":"E4648","DOI":"10.1073\/pnas.1704698114","volume":"114","author":"ME Larson","year":"2017","unstructured":"Larson ME, Greimel SJ, Amar F, LaCroix M, Boyle G, Sherman MA, et al. Selective Lowering of synapsins induced by oligomeric alpha-synuclein exacerbates memory deficits. Proc Natl Acad Sci U S A. 2017;114(23):E4648\u201357.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"886_CR105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuron.2009.12.023","volume":"65","author":"VM Nemani","year":"2010","unstructured":"Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65(1):66\u201379.","journal-title":"Neuron"},{"issue":"29","key":"886_CR106","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","volume":"36","author":"JR Mazzulli","year":"2016","unstructured":"Mazzulli JR, Zunke F, Tsunemi T, Toker NJ, Jeon S, Burbulla LF, et al. Activation of beta-Glucocerebrosidase reduces pathological alpha-Synuclein and restores lysosomal function in parkinson\u2019s patient midbrain neurons. J Neurosci. 2016;36(29):7693\u2013706.","journal-title":"J Neurosci"},{"issue":"23","key":"886_CR107","doi-asserted-by":"crossref","first-page":"eadq2742","DOI":"10.1126\/sciadv.adq2742","volume":"11","author":"Y Schneider","year":"2025","unstructured":"Schneider Y, Koller A, Schweigert A, Andert M, Hoffmann L, O\u2019Brien S, et al. Vimentin network dysregulation mediates neurite deficits in SNCA duplication parkinson\u2019s patient-derived midbrain neurons. Sci Adv. 2025;11(23):eadq2742.","journal-title":"Sci Adv"},{"issue":"8","key":"886_CR108","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/0883073821989154","volume":"36","author":"C Schwering","year":"2021","unstructured":"Schwering C, Kammler G, Wibbeler E, Christner M, Knobloch JK, Nickel M, et al. Development of the Hamburg best practice guidelines for ICV-Enzyme replacement therapy (ERT) in CLN2 disease based on 6 years treatment experience in 48 patients. J Child Neurol. 2021;36(8):635\u201341.","journal-title":"J Child Neurol"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00886-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00886-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00886-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:02:27Z","timestamp":1793304147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00886-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":108,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["886"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00886-1","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The use of both non-transgenic and transgenic mice in this study was conducted with ethical approval from the respective regulatory authorities. The experiments involving\n                      Ctsd\n                      KO mice and their non-transgenic littermates were approved by the Ministry of Energy, Agriculture, the Environment, and Rural Areas of Schleswig-Holstein under reference number V242\u201340536\/2016 (81\u20136\/16). Similarly, the use of Thy1 SNCA mice was approved by the Government of Lower Franconia, Bavaria, Germany, under reference number RUF-55.2.2-2532-2-1489.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ARAM, PS and FZ are named as inventors on the patent: US 12,053,510 B2, #WO2019211320A1; \u2018Treatment of neuronal ceroid lipofuscinosis\u2019.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"95"}}